What MDR CE marking means
MDR CE marking is the route a medical device follows to show conformity with Regulation (EU) 2017/745 before it is placed on the EU market. It is not a marketing badge, a general quality award, or an approval issued by the European Commission. In practice, the first question for many manufacturers is whether the device can be self-declared or whether an MDR-designated notified body must be involved.
Since the MDR became applicable on 26 May 2021, CE marking has depended more heavily on documented clinical evidence, technical documentation, post-market surveillance, economic operator controls, UDI data, and, increasingly, EUDAMED registration. Legacy devices may still benefit from extended transition periods, but only where the legal conditions are met. For related regulatory updates, see the Regulatory section.
The MDR CE route in practical terms
The CE route starts with the manufacturer’s intended purpose. A product is assessed as a medical device only if that intended purpose falls within the MDR definition. The intended purpose then drives the classification, the applicable conformity assessment route, the evidence needed in the technical file, and the level of notified body involvement.
Under the MDR, the manufacturer must demonstrate conformity with the General Safety and Performance Requirements in Annex I, prepare technical documentation under Annex II, establish post-market surveillance documentation under Annex III, draw up an EU declaration of conformity under Article 19 and Annex IV, and affix the CE marking according to Article 20 and Annex V. Where a notified body is required, the CE mark is followed by the notified body’s identification number.
Class I devices usually follow the simplest route when they are non-sterile, have no measuring function, and are not reusable surgical instruments. Class I sterile devices, Class I measuring devices, and Class I reusable surgical instruments require notified body involvement for the relevant sterile, measuring, or reusable aspects. Class IIa, Class IIb, and Class III devices normally require notified body assessment before CE marking.
| Device situation | Typical MDR CE implication | Key evidence focus |
|---|---|---|
| Class I without sterile, measuring, or reusable surgical features | Manufacturer may self-declare conformity if all MDR requirements are met | GSPR checklist, technical documentation, PMS plan, labeling, declaration of conformity |
| Class I sterile, measuring, or reusable surgical instrument | Notified body involvement is limited to the applicable special aspect | Sterility controls, measurement performance, reprocessing and reuse instructions |
| Class IIa or Class IIb | Notified body assessment is normally required before CE marking | Clinical evaluation, QMS, risk management, technical documentation, PMS and PMCF where needed |
| Class III | Highest level of scrutiny, with notified body assessment and more demanding clinical evidence expectations | Clinical evidence, benefit-risk analysis, technical documentation, PMS, PMCF, and traceability |
How MDR changed CE marking compared with the old directives
The MDR did not simply rename the Medical Devices Directive system. It replaced the directives with a directly applicable regulation and expanded the compliance work behind the CE mark. The main change is that CE marking now relies on a more connected evidence system across the full product lifecycle.
Manufacturers need a clear link between intended purpose, claims, risk classification, clinical evaluation, risk management, usability, labeling, and post-market surveillance. A technical file that describes the device but does not connect the evidence to specific MDR requirements is unlikely to be persuasive in a notified body review.
The MDR also strengthened requirements for economic operators. Non-EU manufacturers need an EU authorised representative before placing devices on the EU market. Importers and distributors have defined verification and traceability responsibilities. Manufacturers must also ensure they have a person responsible for regulatory compliance, subject to the conditions and flexibility set out in the MDR and related MDCG guidance.
UDI and EUDAMED are another major shift. They do not replace CE marking, but they increasingly shape the practical CE workflow because device identifiers, actor registration, certificates, and device registration data must align with the technical documentation and labeling strategy.
Transition dates that still matter in 2026
As of October 2026, MDR CE planning still needs to separate new MDR devices from eligible legacy devices. A new device placed on the EU market normally needs to follow the MDR conformity route. A legacy device may continue under extended transition rules only if it falls within the relevant transitional provisions and the manufacturer satisfies the applicable conditions.
Regulation (EU) 2023/607 extended certain MDR transition periods. In broad terms, eligible higher-risk legacy devices, including Class III devices and most Class IIb implantable devices, may have a transition period until 31 December 2027. Eligible medium and lower-risk devices, including other Class IIb devices, Class IIa devices, and certain Class I devices requiring notified body involvement under the MDR, may have a transition period until 31 December 2028.
These dates are not automatic grace periods for every product. The transition depends on conditions such as continued compliance with the previous directive, no significant change in design or intended purpose, no unacceptable risk to health or safety, implementation of an MDR-compliant quality management system, and timely engagement with a notified body. Manufacturers that missed the required application and agreement milestones cannot assume the extended dates apply.
| Date | Regulatory significance |
|---|---|
| 26 May 2021 | The MDR became applicable and replaced the former medical device directives for new MDR conformity routes. |
| 15 March 2023 | Regulation (EU) 2023/607 was adopted to extend certain MDR transition periods and remove the former sell-off deadline. |
| 13 June 2024 | Regulation (EU) 2024/1860 introduced changes including the gradual roll-out of EUDAMED and supply interruption obligations. |
| 28 May 2026 | The first four EUDAMED modules became mandatory to use, according to the European Commission’s implementation notice. |
| 31 December 2027 | End date for eligible higher-risk legacy devices, including Class III and most Class IIb implantable devices. |
| 31 December 2028 | End date for eligible medium and lower-risk legacy devices covered by the extended MDR transition. |
The European Commission also proposed targeted simplification of the medical device rules on 16 December 2025. That proposal is relevant for policy monitoring, but it should not be treated as binding law unless and until it is adopted through the ordinary legislative procedure.
EUDAMED and UDI now affect the CE workflow
EUDAMED is no longer only a future planning item. The European Commission states that, from 28 May 2026, the first four modules are mandatory: actor registration, UDI and device registration, notified bodies and certificates, and market surveillance. For manufacturers, the actor, UDI/device, and certificate-related modules are the most visible in day-to-day MDR CE planning. See also: Implants.
This matters because CE marking is not only a label event at the end of the project. Device data, Basic UDI-DI structure, single registration number, certificate information, and technical documentation need to be consistent. A mismatch between labeling, the declaration of conformity, certificate scope, device registration data, and the technical file can create avoidable delays.
Not all EUDAMED modules were fully available at the same time. The Commission has described the vigilance and post-market surveillance module and the clinical investigations and performance studies module as still under development in the phased roll-out. Manufacturers should therefore separate mandatory current registrations from future module obligations, while keeping internal data ready for later use.
Common gaps that slow MDR CE certification
Notified body capacity remains a practical issue for MDR CE projects. Team-NB’s 2025 medical device survey reported that, among its member notified bodies, the most common average time to issue a new MDR certificate was 13 to 18 months. Some reported longer timelines. That does not mean every project will take that long, but it shows why incomplete submissions and weak evidence packages can be costly.
The problems that slow a review are often basic evidence and consistency gaps rather than obscure regulatory points:
- Unclear intended purpose: claims in brochures, labeling, software screens, or training materials do not match the declared intended purpose.
- Weak classification rationale: the chosen class is not tied clearly to MDR classification rules and device characteristics.
- Incomplete GSPR mapping: the checklist lists standards or documents but does not explain how the evidence demonstrates conformity.
- Clinical evaluation gaps: equivalence, state of the art, clinical benefit, residual risks, and PMCF planning are not sufficiently connected.
- PMS not integrated: post-market surveillance outputs do not feed back into risk management, clinical evaluation, labeling, or corrective actions.
- Labeling and language issues: instructions for use, symbols, warnings, translations, and claims are not aligned across markets.
- Change control problems: design or intended-purpose changes are made without a clear assessment of their MDR impact.
A useful MDR CE readiness review should therefore start before the notified body submission. It should compare the intended purpose, classification, applicable standards, GSPR evidence, clinical evaluation, PMS plan, risk management file, labeling, UDI data, and declaration of conformity as one connected package.
Frequently asked questions
Is MDR CE marking the same as FDA clearance?
No. MDR CE marking is an EU conformity system based on Regulation (EU) 2017/745. FDA clearance or approval follows United States law and is assessed through separate FDA pathways. A device may need both, but one does not replace the other.
Can a Class I device self-declare MDR CE conformity?
Some Class I devices can be self-declared if they meet all MDR requirements and do not require notified body involvement. Class I sterile devices, Class I measuring devices, and Class I reusable surgical instruments still require notified body involvement for the relevant aspects.
Does a legacy CE certificate remain valid until 2028?
Not automatically. The 2027 and 2028 dates apply only to eligible legacy devices that meet the transitional conditions. Manufacturers should verify the device class, certificate history, notified body engagement, design changes, QMS status, and any safety concerns before relying on an extended transition period.
Does the CE mark need the notified body number?
Where a notified body is involved in the applicable conformity assessment procedure, the CE marking is followed by the notified body’s identification number. If a device is validly self-declared without notified body involvement, that number is not added.
What is the main takeaway for MDR CE planning?
The main takeaway is that MDR CE marking is a lifecycle compliance process. Strong submissions connect classification, clinical evidence, risk management, technical documentation, PMS, UDI data, EUDAMED obligations, labeling, and economic operator responsibilities instead of treating CE marking as a final administrative step.